FDA approves Viekira Pak to treat hepatitis C
The U.S. Food and Drug Administration today approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis.
Source: Food and Drug Administration - Category: American Health Source Type: news
More News: American Health | Cirrhosis | Food and Drug Administration (FDA) | Hepatitis | Hepatitis C | Liver | Liver Disease | Norvir | Urology & Nephrology